FDA AdCom reviews motavizumab

RNS Number : 9965M
AstraZeneca PLC
03 June 2010
 



FDA Advisory Committee Reviews MedImmune's Motavizumab

 

MedImmune, AstraZeneca's biologics unit, today announced that the US Food and Drug Administration's (FDA) Antiviral Drugs Advisory Committee has voted 14 to 3 to recommend that motavizumab should not be licensed for marketing regarding the prevention of serious respiratory syncytial virus (RSV) disease in high-risk infants.

 

The committee's recommendation will be considered by FDA reviewers in their evaluation of the Biologics License Application (BLA) for motavizumab.

 

"We continue to believe motavizumab offers a meaningful clinical benefit to patients at high risk for a very common and serious illness," said Genevieve Losonsky, M.D., Vice President, Clinical Development, Infectious Disease at MedImmune.

 

"We thank the committee for the thoroughness of its review. We will work to address the issues raised by the committee and look forward to continuing to work with the FDA as it completes its review of our application."

 

 

NOTES TO EDITORS:

 

About RSV

Each year, up to 125,000 infants in the US are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV.

 

About Motavizumab

Motavizumab is an investigational humanized monoclonal antibody being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease.  It is currently under review at the US FDA.

 

About MedImmune

MedImmune, the worldwide biologics unit for AstraZeneca PLC, has approximately 3,300 employees worldwide and is headquartered in Gaithersburg, Maryland, USA. For more information, visit MedImmune's website at www.medimmune.com

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit: www.astrazeneca.com

 

 

Media Enquiries UK:



Neil McCrae

+44 20 7304 5045  (24 hours)


Chris Sampson

+44 20 7304 5130  (24 hours)


Sarah Lindgreen

+44 20 7304 5033  (24 hours)


Abigail Baron

+44 20 7304 5034  (24 hours)





Investor Enquiries UK:



Jonathan Hunt

+44 207 304 5087

mob: +44 7775 704032

Karl Hård

+44 207 304 5322

mob: +44 7789 654364

Clive Morris

+44 207 304 5084

mob: +44 7710 031012




Investor Enquiries US:



Ed Seage

+1 302 886 4065

mob: +1 302 373 1361

Jorgen Winroth

+1 212 579 0506

mob: +1 917 612 4043

 

 

3 June 2010

 

- ENDS -


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAPLIFSERLIVIII

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings